Nothing said here yet.
to join the conversation.
| Saxonov SergeChief Executive Officer | Sell | 9,900 | $810.1K | Tue, Sep 22 |
| Saxonov SergeChief Executive Officer | Sell | 9,300 | $752.4K | Tue, Sep 22 |
| Saxonov SergeChief Executive Officer | Sell | 2,800 | $230.6K | Tue, Sep 22 |
| SULIMAN SHEHNAAZDirector | Sell | 2,270 | $185.4K | Tue, Sep 22 |
| Saxonov SergeChief Executive Officer | Sell | 2,000 | $159.2K | Tue, Sep 22 |
| SULIMAN SHEHNAAZDirector | Sell | 1,325 | $107.1K | Tue, Sep 22 |
| SULIMAN SHEHNAAZDirector | Sell | 1,222 | $100.5K | Tue, Sep 22 |
| Saxonov SergeChief Executive Officer | Sell | 1,000 | $78.2K | Tue, Sep 22 |
| SULIMAN SHEHNAAZDirector | Sell | 614 | $48.8K | Tue, Sep 22 |
| SULIMAN SHEHNAAZDirector | Sell | 292 | $22.8K | Tue, Sep 22 |
| Taich AdamChief Financial Officer | Sell | 31,428 | $2.0M | Wed, Sep 9 |
| Taich AdamChief Financial Officer | Sell | 13,754 | $897.5K | Wed, Sep 9 |
For questions about this article or underlying research, email [email protected].
10x Genomics has delivered a very strong share price run, and the question now is whether the current valuation can be supported by its sales.
Analysts have lifted their Fair Value estimate for 10x Genomics from about US$62.13 to about US$75.67, a change of roughly 22% in the latest round of models.
What a fantastic six months it’s been for 10x Genomics. Shares of the company have skyrocketed 187%, hitting $72.70. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 6.1% in the morning session after Bank of America raised its price target on the stock to $80 from $50 while keeping a Neutral rating.
In early October 2026, 10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to apply its Flex Apex, Xenium and, later, Atera platforms to biomarker discovery in advanced bladder cancer and residual disease detection…
10x Genomics (TXG) has just pushed its spatial biology story forward with first commercial shipments of the Atera platform, and the launch of the Sentira cloud analysis environment is grabbing investor attention.
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 2.8% in the afternoon session after Argus analyst John Eade initiated coverage on the company with a Buy rating.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector.
10x Genomics has delivered an unusually strong share price run over the past year, which puts a spotlight on whether the current valuation lines up with its sales base.
10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.